GeoVax Labs Net Loss History

GOVX Stock  USD 1.09  -0.06  -5.22%   
Net Loss stood at -21.5 M as of December 31, 2025. Over the last 16 observed reporting periods, Net Loss has trended lower with moderate statistical consistency (R² 0.64). View All Fundamentals
 
Net Loss  
 First Reported
2000-03-31
 Previous Quarter
-4.4 M
 Current Value
-4.4 M
 Quarterly Volatility
2.4 M
Macro event markers
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Latest GeoVax Labs Net Loss Growth Pattern

Net Loss10 Years Trend
Moderate Decline
   Net Income   
       Timeline  

Net Loss Trend Statistics

GeoVax Labs reports Net Loss with a coefficient of variation of 215.7% over 15 periods, reflecting wide dispersion driven primarily by directional growth rather than instability. R-squared at 0.64 is consistent with a strong linear fit indicating consistent directional movement.
Arithmetic Mean-6,717,246
Geometric Mean 6,190,868
Coefficient Of Variation-215.70
Mean Deviation 10,006,815
Median-2,733,555
Standard Deviation 14,489,225
Sample Variance209.9T
Range62.6M
R-Value-0.80
Mean Square Error80.2T
R-Squared 0.64
Significance 0.0001
Slope-2,299,129
Total Sum of Squares3359T

GeoVax Labs Net Loss History

GeoVax Labs' Net Loss is tracked from 2012 through 2026, spanning 15 reported values, moving from -2.1 M to -20.4 M.
2026-20.4 M
2025-21.5 M
2024-25 M
2023-26 M
2022-14 M
2021-18.5 M
2020-2.9 M
2019-2.4 M
2018-2.6 M
2017-2.2 M
2016-3.3 M
2015-2.7 M
2014-2.7 M
2013-2.3 M
2012-2.1 M

Correlation of Net Loss With Other Accounts

Below are pairwise correlations of GeoVax Labs' Net Loss with other financial line items. Coefficients range from −1 (perfect inverse) to +1 (perfect co-movement). These values describe historical association and do not imply causation.

Related Fundamentals

Last ReportedEnd Of Year Estimate
Price To Sales Ratio 1.65 1.57
Days Sales Outstanding 69.99 118.79
Book Value Per ShareM4.2 M
Free Cash Flow Yield-524.16%-498.00%

Methodology, Assumptions & Data Sources

The data below presents GeoVax Labs's Net Loss through recent fiscal years. Period-over-period changes in this line item trace to underlying business decisions visible in the financial statements. As a Biotechnology company, GeoVax Labs' Net Loss should be benchmarked against sector peers for meaningful interpretation.

Reported values for GeoVax Labs are derived from periodic company reporting and market reference feeds and standardized for analysis. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.

Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board